237 related articles for article (PubMed ID: 16470953)
1. Trastuzumab in breast cancer.
Mastrianni DM
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
[No Abstract] [Full Text] [Related]
2. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Hillner BE; Smith TJ
J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
[No Abstract] [Full Text] [Related]
3. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
de Lima Lopes G; Gluck S
J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
[No Abstract] [Full Text] [Related]
4. How much will Herceptin really cost?
Barrett A; Roques T; Small M; Smith RD
BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
6. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
Smith M
J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
[No Abstract] [Full Text] [Related]
7. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
Offerhaus L
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
[No Abstract] [Full Text] [Related]
8. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
9. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in breast cancer.
Gounaris IG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
[No Abstract] [Full Text] [Related]
11. Adjuvant trastuzumab for breast cancer: the other side of the coin.
Gopalakrishnan S; Linnane J
BMJ; 2005 Nov; 331(7526):1202-3. PubMed ID: 16293846
[No Abstract] [Full Text] [Related]
12. Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.
McLaren EH
BMJ; 2005 Nov; 331(7526):1203. PubMed ID: 16293854
[No Abstract] [Full Text] [Related]
13. Trastuzumab in breast cancer.
Banna GL; Santoro A
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
[No Abstract] [Full Text] [Related]
14. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
15. Trastuzumab and capecitabine for metastatic breast cancer.
Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
[No Abstract] [Full Text] [Related]
16. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
Grove ML
BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
[No Abstract] [Full Text] [Related]
17. Adjuvant trastuzumab for breast cancer.
Dent R; Clemons M
BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471
[No Abstract] [Full Text] [Related]
18. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing: the patent "genee" is out of the bottle.
Goldman B
CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
[No Abstract] [Full Text] [Related]
20. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
